Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
- Increase in total revenue to 156.9 Mio. EUR after three quarters - Increase in result (DVFA/SG) above average to 6.7 Mio. Euro - Equity ratio increases to 20.3%

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@


Berlin, 9th May 2006. The first three quarters of the trading year 2005/2006 have brought an increase in revenue of 3.1% for the Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA), up from 152.1 Mio. EUR in the previous year to 156.9 Mio. EUR. Results by DVFA/SG (IFRS) were up from 6.4 Mio. EUR to 6.7 Mio. EUR in the current year. The result per stock reached 0.55 EUR, compared to 0.53 EUR in the same time period of the previous year. The equity ration increased from 16.7% to 20.3% and the quota of financial liabilities decreased due to Sale-and-lease-back transactions.

Both revenue and results continued to develop positively in the core segment Care, in which the Marseille clinics represent 80% of the total bed-capacity of the corporation. With revenues of 118.8 Mio. EUR, Marseille clinics have achieved a revenue growth of 7.5 Mio. EUR, compared to 111.3 Mio. EUR revenue in the same period of the previous year. Results as indicated by DVFA/SG (IFRS) increased by 0.8 Mio. EUR from 9.3 Mio. EUR to now 10.1 Mio. EUR, in combination with an expansion of capacity and an increase in utilisation of 90.5% to now 91.7%.

In the segment of Rehabilitation the month of January stayed below expectations for the 3rd quarter. Thus the average utilisation decreased from 75.8% in the previous year to 74.9%. Utilisation as calculated for the full corporation therefore fell from 89.3% to 88.6%. Revenue in the period of the report fell by 3.8 Mio. EUR to 35.3 Mio. EUR from 39.1 Mio. EUR, due to capacity cutbacks. Results based on DVFA/SG (IFRS) were -3.4 Mio. EUR with -2.2 Mio. EUR in the third quarter and stayed below the value of -2.9 Mio. EUR in the previous year.

It is our forecast that the positive development in the Care segment will accelerate in the fourth quarter and will continue to represent the value driver for the total group. For the rehabilitation segment the company expects a result for the fourth quarter comparable to the first and second quarters. Results for the full year are expected to be unchanged in comparison to the previous year, due to a slight decline in profit in the third quarter  of -2.2 Mio. EUR. For the full year of 2005/2006 management is therefore expecting the continuation of the development of total revenue and above average increases in results for the complete Marseille group, in comparison to the previous year.

End of ad hoc announcement

@@start.t2@@end of announcement                                                 euro adhoc 09.05.2006 09:50:28

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar:

Further inquiry note:
Marseille-Kliniken AG Hillermann Consulting
Axel Hölzer             Christian Hillermann
CEO                          Geschäftsführer
Alte Jakobstraße 79/80 Eppendorfer Baum 5
10709 Berlin             20249 Hamburg
Tel.: 030 / 246 32-400 Tel.: 040 / 414069-13
Fax: 030 / 246 32-401 Fax: 040 / 414069-14

Branche: Pharmaceuticals
ISIN:      DE0007783003
WKN:        778300
Index:    CDAX, Classic All Share, Prime All Share
Börsen:  Frankfurter Wertpapierbörse / official dealing/prime standard
              Börse Berlin-Bremen / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Hamburger Wertpapierbörse / official dealing

Weitere Meldungen: Marseille-Kliniken AG

Das könnte Sie auch interessieren: